SELEGILINE TRANSDERMAL SYSTEM IN LEVADOPA/CARBIDOPA PARKINSON'S PATIENTS

左旋多巴/卡比多巴帕金森病患者的司来吉兰透皮系统

• 批准号: 6113786
• 负责人: ROGER M KURLAN
• 金额: $ 1.48万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113786
• 关键词: Parkinson's disease; antiparkinson drugs; brain disorder chemotherapy; clinical research; combination chemotherapy; deprenyl; dihydroxyphenylalanine; dopamine agonists; drug screening /evaluation; human subject; human therapy evaluation; pharmacokinetics; transdermal drug delivery

The objectives of this study are to examine the symptomatic benefit of the Selegiline Transdermal System (STS) as adjunctive therapy to levodopa/carbidopa treated Parkinson's Disease patients. Also to examine safety and tolerability of the Selegiline Transdermal System (STS) in levadopa/carbidopa treated Parkinson's Disease Patients.

本研究的目的是检查司来吉兰透皮系统（STS）作为左旋多巴/卡比多巴治疗的帕金森病患者的连续治疗的症状益处。 还检查司来吉兰透皮系统（STS）在左旋多巴/卡比多巴治疗的帕金森病患者中的安全性和耐受性。